FOXO TECHNOLOGIES Stock Price, News & Analysis

FOXO Technologies (NYSE American: FOXO) announced that its behavioral health subsidiary, Myrtle Recovery Centers, has successfully renewed its operating license for its Oneida, Tennessee facility for another year. The renewal was granted by Tennessee's Department of Mental Health and Substance Abuse Services following a successful annual inspection.

The facility, which provides alcohol and drug residential treatment services, is currently operating at full capacity with a waiting list for future admissions. Management is actively exploring strategic expansion options, including opening a second location and potential acquisitions in the behavioral health sector.

FOXO Technologies Inc. (NYSE American: FOXO) has announced its Board's approval to pursue the spin-off of its subsidiary, FOXO Labs, Inc., which specializes in epigenetics technology. The subsidiary owns Patent No. 11,817,214 for machine learning models that determine biochemical states using DNA epigenetic data.

FOXO Labs utilizes saliva-based epigenetic biomarkers to provide health, lifestyle, and longevity insights, eliminating the need for invasive blood and urine collection. The company is developing an AI-powered health coaching system that combines wearable data with epigenetic analysis to deliver personalized wellness guidance.

The spin-off aims to create a subscription-based revenue model for personal health and longevity, with FOXO Technologies maintaining partial ownership while allowing shareholders to benefit from direct ownership in FOXO Labs.

FOXO Technologies (NYSE American: FOXO) has announced a 1-for-1.99 reverse stock split of its Class A common stock, effective July 27, 2025, at 4:01 PM ET. The stock will begin trading on a split-adjusted basis on July 28, 2025, under the same symbol but with a new CUSIP number.

The reverse split was approved on June 23, 2025, by a majority stockholder and aims to ensure compliance with NYSE American's continued listing requirement of maintaining a stock price above $0.10 per share. Fractional shares will be rounded up to the next whole number, and all outstanding securities, including preferred stock, debt, options, warrants, and equity incentive plans, will be proportionally adjusted.

FOXO Technologies Inc. (NYSE American: FOXO) announced that its behavioral health subsidiary, Myrtle Recovery Centers, has secured approval for Scott County Opioid Abatement Funds for a second consecutive year. The funding, effective July 1, 2025, will support care for uninsured patients from Scott County at the company's Oneida, Tennessee facility.

The facility is currently operating at full capacity with a patient waiting list, demonstrating strong demand for its services. Myrtle's CEO Robert Merritt highlighted this as validation of their clinical team's quality of care. FOXO's CEO Seamus Lagan indicated plans for expansion through organic growth and acquisitions, expecting Myrtle to become a significant revenue contributor to FOXO in the future.

FOXO Technologies (NYSE American: FOXO) has designated a new Series E Cumulative Redeemable Secured Preferred Stock to support its acquisition strategy. The Series E Preferred Stock features include a $25.00 per share stated value, 2.5% annual cash dividend (paid semi-annually), 5.0% annual common stock dividend (paid semi-annually), and security interest in FOXO Acquisition Corporation.

The company plans to use this preferred stock as both acquisition currency and for capital raising, with intentions to have it publicly listed with its own trading symbol. CEO Seamus Lagan emphasized this non-dilutive funding mechanism's potential to increase net revenues and cash flow through strategic acquisitions.

FOXO Technologies Inc. (NYSE American: FOXO) has announced that its Big South Fork Medical Center in Oneida, Tennessee, has begun offering wound care services for both inpatient and outpatient treatment. The expansion addresses growing demand in the service area, particularly focusing on diabetic patients who face challenges with wound healing due to excessive inflammation and reduced angiogenesis. CEO Seamus Lagan indicated that this service expansion is expected to increase net revenues, and the company is exploring additional service offerings at the Oneida campus and other regional locations.

FOXO Technologies has announced the formation of FOXO Acquisition Corporation, a new wholly-owned subsidiary aimed at acquiring healthcare services companies. The company plans to create a new series of non-convertible preferred stock that will be publicly listed with its own trading symbol, designed to generate cash and common stock dividends while providing secured interest in the acquisition vehicle. CEO Seamus Lagan emphasized this move as a non-dilutive funding approach targeting acquisitions with growth potential. Additionally, the company announced the passing of Interim CFO Martin Ward on June 9, 2025, with CEO Lagan temporarily assuming the CFO role while a permanent replacement is sought.

FOXO Technologies has secured a significant equity funding agreement, issuing 1,650 shares of Series A Preferred Stock for net proceeds of $1.5 million. The agreement with existing institutional investors involves three closings of 550 shares each, with the first closing on June 4, 2025. The company reported strong Q1 2025 performance with over $3M in net revenues and improved stockholders' equity by $4.4M. Notable is the transformation in stockholders' equity from negative $17.5M in September 2024 to positive $9.7M by March 2025. CEO Seamus Lagan indicated plans to close recently announced acquisition targets and continue focusing on revenue growth and balance sheet improvement.

FOXO Technologies Inc. (NYSE American: FOXO) announced the expansion of services at its Big South Fork Medical Center in Oneida, Tennessee, to include wound care services starting June 2, 2025. The hospital, which currently serves over 600 emergency room patients and 300 outpatients monthly, will offer both inpatient and outpatient wound care services.

The expansion addresses a growing need for wound care services, particularly for diabetic patients. According to the CDC, as of 2021, over 38 million diabetes patients existed in the U.S., with up to 15% experiencing diabetic foot ulcers. The hospital is currently reconfiguring space and making key clinical hires to support this initiative.